SCHEMBL4674845

SCHEMBL4674845

Cc1ccc(-c2ccoc2C(=O)C=C(O)c2nc[nH]n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPC1 O15118 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
HPGD P15428 2/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 2/20 0.31
HTT P42858 1/20 0.31
RECQL P46063 1/20 0.31
KIT P10721 1/20 0.31
PDGFRA P16234 1/20 0.31
KDR P35968 1/20 0.31
PKM P14618 1/20 0.30
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673273 0.90 MAPK14 (0.34) HCRTR1HCRTR2L3MBTL1NPC1KDM4E
SCHEMBL4679875 0.90 HCRTR1 (0.35) HCRTR1HCRTR2ALDH1A1LMNA
SCHEMBL4672819 0.89 KMO (0.33) MAPTALPL
SCHEMBL4672277 0.87 KMO (0.37) HCRTR1HCRTR2L3MBTL1NPC1SMN1; SMN2
SCHEMBL27555769 0.82 LRRK2 (0.32) ALDH1A1PKM
SCHEMBL4674674 0.82 TP53 (0.35) NPC1SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL4673110 0.81 ICAM1 (0.32) L3MBTL1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL4675408 0.81 TP53 (0.32) L3MBTL1NPC1SMN1; SMN2MEN1MAPT
SCHEMBL4672775 0.81 KMO (0.37) L3MBTL1NPC1SMN1; SMN2MEN1ALDH1A1
SCHEMBL4671952 0.81 KMO (0.37) SMN1; SMN2MAPTKDM4ELMNAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCRTR1 162/4885HCRTR2 536/4885L3MBTL1 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.